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ABSTRACT  
This prospective cohort study of 622 women living with HIV from Johannesburg (2012) detected MG 
in 7.4%(95%CI:5.5-9.7, 46/622), with detection more likely with lower CD4 counts(AOR 1.02 per 10 
cells/ L decrease, 95%CI:1.00-1.03) and higher plasma HIV-1 RNA(AOR 1.15 per log copies/mL 
increase, 95%CI:1.03-1.27). No mutations for macrolide/quinolone resistance was detected. 
 
Keywords: Mycoplasma genitalium, women, HIV, sexually transmitted infections, antimicrobial 
resistance 
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BACKGROUND 
Mycoplasma genitalium(MG) is a sexually transmitted pathogen associated with non-gonococcal 
urethritis in males,[1] cervicitis and pelvic inflammatory disease(PID).[2] There is an association of 
MG with HIV acquisition,[3] but it is unclear how HIV affects MG epidemiology and whether MG has 
a role in HIV progression. If left undetected, inadequately treated MG may contribute to 
reproductive morbidity in women and development of antimicrobial resistance(AMR).[4] MG has a 
high propensity for developing AMR, particularly to macrolides used for syndromic sexually 
transmitted infection(STI) management in low- and middle-income countries(LMIC).[5]  
 
This study aims to determine the prevalence, persistence/reinfections and risk factors associated 
with MG in a cohort of women living with HIV (WLHIV) in South Africa. We report MG-AMR profile 
for both macrolides and fluoroquinolones. 
 
METHODS 
Study population 
Cervical specimens were collected as part of an evaluation study of cervical cancer screening 
strategies in Burkina Faso and South Africa, as previously described.[6] Inclusion criteria were 
WLHIV, aged 25-50 years, and resided in Ouagadougou or Johannesburg. This analysis focuses on 
WLHIV recruited in South Africa, as MG rates were found to be low in Burkina Faso(4/615). WLHIV 
were recruited from primary health care centres and surrounding communities in Johannesburg 
from December 2011 to October 2012.  
 
Specimen collection and laboratory analysis 
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For all women at baseline and endline, a cervical swab was collected to detect Chlamydia 
trachomatis, Neisseria gonorrhoeae, MG, and Trichomonas vaginalis using a validated in-house real-
time multiplex polymerase chain reaction(mPCR) assay. For the endline, not all samples could be 
tested for cervical PCR, and we only report MG testing for those found positive at baseline. 
Specimens that tested MG positive with the in-house mPCR assay were confirmed with the 
commercial Sacace MG real-time PCR assay(Sacace Biotechnologies, Como, Italy). All real-time PCR 
assays were performed using the Rotor-Gene platform(Qiagen, Hilden, Germany). A vaginal smear 
was Gram-stained for the diagnosis of bacterial vaginosis(Nugent’s score of at least 7) and Candida 
spp. 
Venous blood was taken to perform herpes simplex virus type 2(HSV-2) serology(Kalon IgG2 ELISA, 
Kalon Diagnostics, Guilford, UK), Treponema pallidum hemagglutination and rapid plasma 
reagin(Omega Diagnostics, Cape Town, South Africa), HIV-1 plasma viral load(Cobas Taqman, Roche 
Diagnostics, Johannesburg, South Africa) and CD4+ T-lymphocyte count(FACScount, Becton-
Dickinson, Franklin Lakes, New Jersey, USA). 
 
MG-AMR testing 
Macrolide resistance associated mutations in region V of the 23S rRNA gene of MG(positions A2058 
and A2059 using Escherichia coli numbering) was determined.[7] Mutations in the region 
corresponding to the quinolone resistance determining region(QRDR) of the DNA gyrase(gyrA only) 
and the topoisomerase IV genes(parC only) were analysed.[8] To visualize PCR products, 1µl of PCR 
products, including a 1000bp marker were run on an Agilent 2100 Bioanalyzer(Agilent Technologies, 
Santa Clara, USA). The PCR products were purified using the MSB Spin PCRapace kit(Invitek, Berlin, 
Germany). After purification of the PCR products, cycle sequencing reactions were performed in 
both directions using the same primers that were used for amplification. The cycle sequencing 
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reactions were performed using the ABI Prism Big Dye terminator reaction kit version 3.1(Applied 
Biosystems, Foster City, CA) and analysed on a 16-capillary ABI 3130xl Genetic Analyzer(Applied 
Biosystems, Foster City, CA). Contigs obtained from initial sequencing were aligned using 
Sequencher version 5.4.6(Gene Codes Corporation, MI, USA) and the FASTA sequences obtained 
were aligned(MEGA 7.0.20) and compared with MG reference strains on GenBank(G37, M2288, 
M2321, M6282 and M6320).   
 
Statistical analysis 
Logistic regression analysis was used to explore patient characteristics associated with MG 
detection. We identified variables with p value <0.20, and examined each variable independently in 
separate regression models, adjusted for age, education, and income.  We present adjusted odds 
ratios(AORs) alongside 95% confidence intervals(CI). Data were analyzed using STATA(StataCorp. 
2013). 
 
RESULTS 
623 WLHIV were recruited, and 622 were included in this analysis as one woman was not tested for 
MG. MG was detected in 7.4%(95%CI:5.5-9.7), Trichomonas vaginalis in 16.2%(95%CI:13.4-19.4), 
Chlamydia trachomatis in 5.0%(95%CI:3.4-7.0), Neisseria gonorrhoeae in 2.3%(95%CI:1.2-3.7), BV in 
41.6%(95%CI:37.6-45.6), and Candida spp. in 8.5%(95%CI:6.4-11.0). Overall, MG monoinfection was 
found in 16 women(2.6%), MG with STI/RTI coinfection in 30 women(4.8%), no MG but another 
STI/RTI in 343 women(55.1%) and no MG and no STI/RTI in 233 women(37.5%). 
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Table 1 shows that compared to women with no MG, women with MG were significantly 
younger(mean age 31.8 years vs. 35.2, p<0.001), had more lifetime sexual partners(4.3 vs. 3.7, 
p<0.001), were more likely to have active syphilis(4.4% vs. 0.9%, p=0.032) and more likely to have a 
lower median CD4 count(387 vs. 433 cell/ L, p=0.018) and higher median plasma HIV-1 RNA 
levels(5170 vs. 470 copies/mL, p=0.003). In the multivariable model, detection of MG was more 
likely in women with lower CD4 counts(AOR 1.02 per 10 cells/L decrease) and higher plasma HIV-1 
RNA(AOR 1.15 per log copies/mL increase). There was a significant difference between HIV-1 plasma 
viral loads in women with MG detected(median=5170 copies/mL, IQR:155-4910) compared to those 
who did not(median=470 copies/mL, IQR:44-7820, p=0.003). 
 
MG-AMR 
Macrolide and quinolone resistance testing were conducted for 43 out of the 46 MG-positive 
specimens at baseline as three specimens tested negative for MG when retested in January 2018. 
The following number of specimens produced full readable sequences for the respective genes: 23S 
rRNA(macrolide resistance): 43/43(100%), gyrA(QRDR): 26/43(60.5%) and parC(QRDR): 
43/43(100%). Macrolide resistance-associated mutations were not detected in any of the specimens 
analysed(0/43). Mutations in the QRDR of the gyrA gene were not detected in any of the specimens 
that could be sequenced(0/26) while mutations in the QRDR of the parC gene were detected in 
19/43(44.2%) specimens. The most common mutation in parC was C184T(18/19; 94.7%) resulting in 
the amino acid alteration P62S. The G284T mutation in parC was the only additional mutation that 
resulted in an amino acid change(S95I, 2/19, 10.5%).  
 
For the follow-up, 41 specimens from returning women were tested for RNaseP(human internal 
control) to assess DNA adequacy for PCR and all 41 were valid. We tested for MG using both an in-
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house real-time mPCR and the commercial Sacace MG real-time PCR. A total of 12/41(29.3%) 
specimens tested MG positive with both assays. There were no macrolide resistance-associated 
mutations nor mutations in the gyrA gene. Five out of 12 specimens had parC mutations: the parC 
sequence profiles of the follow-up specimens corresponded to the sequence profiles of the baseline 
specimens in all but one specimen. 
 
Overall, 15/46 women received antibiotics within 3 months of the baseline visit: one woman had 
azithromycin and doxycycline, and 14 women only had doxycycline, which was the recommended 
treatment for genital discharge syndrome in South Africa at the time of this study. Between the first 
and final MG test at a median 16 months later(IQR, 15.6-16.8), 23/46 women received doxycycline 
100mg twice daily for 7 days, three women received azithromycin 1g single dose, two women 
received both doxycycline and azithromycin, and no one received any quinolones.  In total, 18 
women did not receive any antibiotics that has activity against MG between the first and final MG 
test. For the 12 women with detectable MG at follow-up, six (50%) had previously been treated with 
doxycycline and three (25%) with azithromycin. For 29 women who had undetectable MG on follow-
up, 13 (45%) women were treated with doxycycline and one (3%) with azithromycin. 
 
DISCUSSION 
The evidence is accruing for the public health importance of MG and its impact on reproductive 
morbidity. We extend the literature by reporting the prevalence and AMR associated with MG 
among WLHIV in South Africa. We found that MG was as common as other STIs. Nearly a third of 
women with detectable MG at baseline had detectable MG after a median of 16 months. We 
detected no mutations associated with macrolide or quinolone resistance but with the change in 
2015 of guidelines for syndromic management for genital discharge and PID syndromes in replacing 
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doxycycline with azithromycin as the first-line antibiotic, macrolide resistance selection pressure 
may become considerable. This may result in a rapid rise of macrolide resistance as demonstrated in 
countries where macrolides are frequently used.[9] Ongoing monitoring of MG and its AMR profile is 
urgently needed. 
 
Whilst MG may influence HIV acquisition,[10] little is known of reciprocal interactions. We found 
that MG was associated with increased HIV-1 plasma viral load and lower CD4+ cell count, which 
may affect the clearance of STIs. It may be possible that MG persisted because of uncontrolled HIV 
replication and immunosuppression, or, alternatively, MG may increase HIV replication, preventing 
rapid or full CD4 cell recovery. Previous studies have shown that  
 
In conclusion, MG is as common as other cervical STIs among WLHIV in South Africa. We document 
no macrolide/quinolone resistance-associated mutations in 2012 for a group at high risk for STIs. 
However, MG-AMR needs ongoing monitoring given the inclusion of macrolides into national 
guidelines for syndromic management for genital discharge and PID syndromes since 2015.  
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Table 1 Comparison of the demographics, sexual behaviours and laboratory results of Mycoplasma 
genitalium (MG) positive and MG negative women living with HIV in South Africa (n=622) 
 
Variable MG positive (N=46) MG negative (N=576) P value 
 % (n/N) or mean [SD] % (n/N) or mean [SD]  
Demographics    
Mean age (years) [+ SD] 31.8 [+ 4.9] 35.2 + [6.1] <0.001 
Completed high school or above 41.3 (19/46) 43.0 (248/576) 0.817 
Ever smoked 15.2 (7/46) 12.1 (70/576) 0.544 
Not married 95.7 (44/46) 85.4 (492/576) 0.053 
Income (Rand, R$)    
   <1800 58.7 (27/46) 49.9 (288/576)  
   1801-6000 41.3 (19/46) 43.8 (252/576)  
   >6000 0 (0) 6.2 (36/576) 0.312 
Sexual behaviours    
Age at first sex (years) [+ SD] 17.6 [+ 1.7] 17.8 [+ 2.5] 0.369 
Mean lifetime sexual partners [+ SD] 4.3 [+ 2.7] 3.7 [+ 2.5] <0.001 
No sex in the last 3 months 19.6 (9/46) 17.5 (101/576) 0.728 
Same sexual partner in the last 3 months 94.6 (35/37) 92.6 (440/475) 0.657 
Condomless sex with regular sexual partner in the last 3 months 52.8 (19/36) 39.1 (182/464) 0.110 
Condomless sex with casual sexual partner in the last 3 months 0 (0/2) 12.5 (2/16) 0.596 
Laboratory findings    
N. gonorrhoeae 0 (0) 2.4 (14/576) 0.285 
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C. trachomatis 4.4 (2/46) 5.0 (29/576) 0.837 
T. vaginalis 15.2 (7/46) 16.3 (94/576) 0.845 
Bacterial vaginosis 47.8 (22/46) 41.0 (232/565) 0.371 
Candida 10.9 (5/46) 8.5 (47/565) 0.551 
Active syphilis (RPR+/TPHA+)  4.4 (2/46) 0.9 (5/572) 0.032 
HSV-2 serology positive 100.0 (46/46) 94.8 (543/573) 0.112 
HIV parameters    
Years since HIV diagnosis    0.853 
   <5 years 56.5 (26/46) 56.1 (323/576)  
   5-9 years 34.8 (16/46) 32.6 (188/576)  
   > 10 years 8.7 (4/46) 11.3 (65/576)  
Currently on ART 60.9 (28/46) 65.3 (377/576) 0.530 
Median years on ART [IQR] 1.9 [0.8-3.0] 2.4 [0.9-4.2] 0.205 
Self-reported adherence to ART   0.830 
   60-90% 85.7 (24/28) 84.2 (314/373)  
   <60% 14.3 (4/28) 15.8 (59/373)  
Median CD4 count cells/ L [IQR] 387 [273-466] 433 [325-592] 0.018 
Median HIV-1 RNA copies/mL [IQR] 5170 [155-49100] 470 [44-7820] 0.003 
Undetectable plasma HIV-1 RNA (<40 copies/ml) 17.4 (8/46) 23.6 (136/576) 0.336 
ART = antiretroviral therapy; CIN = cervical intraepithelial neoplasia; HSV-2 = herpes simplex virus type 2; IQR = interquartile range; MG = 
Mycoplasma genitalium; SD = standard deviation; RPR =rapid plasma reagin; TPHA = Treponema pallidum hemagglutination assa 
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